Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
- PMID: 39587229
- DOI: 10.1038/s41587-024-02487-7
Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
Erratum in
-
Author Correction: Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system.Nat Biotechnol. 2025 Mar 4. doi: 10.1038/s41587-025-02601-3. Online ahead of print. Nat Biotechnol. 2025. PMID: 40038437 No abstract available.
Abstract
Delivery of biomacromolecules to the central nervous system (CNS) remains challenging because of the restrictive nature of the blood-brain barrier (BBB). We developed a BBB-crossing conjugate (BCC) system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis. Intravenous administration of a BCC10-oligonucleotide conjugate demonstrated effective transportation of the oligonucleotide across the BBB and gene silencing in wild-type mice, human brain tissues and an amyotrophic lateral sclerosis mouse model.
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: Y.D. is a scientific advisor for Arbor Biotechnologies, siRNAgen Therapeutics and Moonwalk Biosciences. Y.D. is a cofounder and holds equity in Immunanoengineering Therapeutics. The other authors declare no competing interests.
References
LinkOut - more resources
Full Text Sources